Lilly targets black market retatrutide

6 minute read


The drug maker behind experimental obesity treatment retatrutide has stepped up its attack on a growing black market for the unapproved peptide.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×